Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of EBT data on file, last reported at -$184.0 million in Q1 2026.

• EBT for Q1 2026 came in at -$184.0 million, down 22.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$605.2 million (down 3829.31% YoY), and the FY2025 annual result was -$571.0 million, down 14175.0% from the prior year.
• EBT eased to -$184.0 million in Q1 2026 per RARE's latest filing, from -$127.7 million in the prior quarter.
• Over five years, EBT peaked at $430.2 million in Q4 2024 and troughed at -$238.8 million in Q3 2022.
• A 5-year average of -$121.8 million and a median of -$153.3 million in 2022 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT tumbled 227.98% in 2022, then surged 437.59% in 2024.
• A 5-year view of EBT shows it stood at -$153.3 million in 2022, then rose by 16.87% to -$127.4 million in 2023, then surged by 437.59% to $430.2 million in 2024, then tumbled by 129.68% to -$127.7 million in 2025, then plunged by 44.1% to -$184.0 million in 2026.
• Business Quant data shows RARE's EBT at -$184.0 million in Q1 2026, -$127.7 million in Q4 2025, and -$179.5 million in Q3 2025.